What GLP-1 actually is
GLP-1, short for glucagon-like peptide-1, is a hormone your gut releases after you eat. It tells your pancreas to release insulin, slows how fast food leaves your stomach, and signals your brain that you’re full. Drugs in this class copy that hormone’s effect, but they last far longer than the natural version, which breaks down within minutes.
Retatrutide and tirzepatide go a step further. Tirzepatide also activates the GIP receptor, and retatrutide activates GIP and glucagon receptors on top of GLP-1. Each added receptor changes appetite, fat use and blood sugar control in a slightly different way, which is part of why trial results differ between the three.
Why the effect builds slowly
The appetite and digestion changes are strongest a few days after each dose, then taper before the next one. Weekly dosing keeps a steady low level in the body instead of sharp peaks and drops.
Why titration exists at all
Starting at a full dose almost always causes nausea severe enough that people stop. Titration schedules raise the dose in fixed steps over several weeks so the gut has time to adjust. Skipping steps, or restarting at the old dose after a long gap, brings the same early side effects back.
What changes between steps
Each step change usually needs one to two weeks to settle before the next increase. A rushed schedule doesn’t get you to the target dose faster in any meaningful way, since most of the benefit comes from staying on a stable dose for months, not from reaching the top step quickly.
Reading trial data versus real-world use
Clinical trial dosing follows a fixed protocol tested on a specific population. People using GLP-1 peptides outside a trial often titrate more slowly if side effects are strong, or adjust the schedule with medical guidance. Neither approach is inherently right, but the two shouldn’t be conflated when comparing results.